Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

Archive ouverte

Roisné-Hamelin, Florian | Pobiega, Sabrina | Jézéquel, Kévin | Miron, Simona | Dépagne, Jordane | Veaute, Xavier | Busso, Didier | Du, Marie-Hélène Le | Callebaut, Isabelle | Charbonnier, Jean-Baptiste | Cuniasse, Philippe | Zinn-Justin, Sophie | Marcand, Stéphane | Park, Keunchil | Özgüroğlu, Mustafa | Vansteenkiste, Johan | Spigel, David | Yang, James C.H. | Ishii, Hidenobu | Garassino, Marina | de Marinis, Filippo | Szczesna, Aleksandra | Polychronis, Andreas | Uslu, Ruchan | Krzakowski, Maciej | Lee, Jong-Seok | Calabrò, Luana | Arén Frontera, Osvaldo | Xiong, Huiling | Bajars, Marcis | Ruisi, Mary | Barlesi, Fabrice

Edité par CCSD ; Lippincott, Williams & Wilkins -

International audience. Abstract Specific proteins present at telomeres ensure chromosome end stability, in large part through unknown mechanisms. In this work, we address how the Saccharomyces cerevisiae ORC-related Rif2 protein protects telomere. We show that the small N-terminal Rif2 BAT motif ( B locks A ddition of T elomeres) previously known to limit telomere elongation and Tel1 activity is also sufficient to block NHEJ and 5’ end resection. The BAT motif inhibits the ability of the Mre11-Rad50-Xrs2 complex (MRX) to capture DNA ends. It acts through a direct contact with Rad50 ATP-binding Head domains. Through genetic approaches guided by structural predictions, we identify residues at the surface of Rad50 that are essential for the interaction with Rif2 and its inhibition. Finally, a docking model predicts how BAT binding could specifically destabilise the DNA-bound state of the MRX complex. From these results, we propose that when an MRX complex approaches a telomere, the Rif2 BAT motif binds MRX Head in its ATP-bound resting state. This antagonises MRX transition to its DNA-bound state, and favours a rapid return to the ATP-bound state. Unable to stably capture the telomere end, the MRX complex cannot proceed with the subsequent steps of NHEJ, Tel1-activation and 5’ resection.

Suggestions

Du même auteur

Mechanism of MRX inhibition by Rif2 at telomeres

Archive ouverte | Roisné-Hamelin, Florian | CCSD

International audience. Specific proteins present at telomeres ensure chromosome end stability, in large part through unknown mechanisms. In this work, we address how the Saccharomyces cerevisiae ORC-related Rif2 pr...

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

Archive ouverte | Park, Keunchil | CCSD

International audience. The JAVELIN Lung 200 phase 3 trial did not meet its primary endpoint of improving overall survival (OS) with avelumab vs docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report po...

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Archive ouverte | Garassino, Marina, Chiara | CCSD

International audience. has a patent T-cell immunotherapy development pending; is a founder and owner of BioCytics, which is a clinical research laboratory developing T-cell immunotherapy; and has previously bought ...

Chargement des enrichissements...